Markers for Prognostic Progress
A combination of new biomarkers could aid decision-making in the clinical management of early-stage lung cancers
Ana Robles |
At a Glance
- Lung cancer is the most fatal cancer, causing nearly one-fifth of all cancer deaths worldwide
- To improve survival, it’s vital to diagnose and treat lung cancer early, so we need better diagnostic and prognostic biomarkers
- A combination of markers, including HOXA9 promoter methylation and blood vessel invasion, may assist with prognosis of early-stage lung cancer
- Ideally, these two biomarkers could be used in combination with a range of others to yield the most detailed picture possible of an individual’s disease
Lung cancer remains the top killer worldwide among cancers, causing nearly one-fifth of all cancer deaths worldwide (1). But not every patient with lung cancer faces the same fate; those diagnosed early have a good prognosis, with one-year net survival rates for stage I cancers at 83 percent (compared with only 17 percent for those diagnosed at stage IV). It’s clear that early diagnosis confers a strong survival benefit – and biomarker analyses that yield prognostic and treatment decision information only compounds this advantage.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!